;PMID: 12117880
;source_file_696.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..25] = [t:0..25]
;1)sentence:[e:30..95] = [t:30..95]
;2)section:[e:99..173] = [t:99..173]
;3)section:[e:177..298] = [t:177..298]
;4)sentence:[e:302..313] = [t:302..313]
;5)sentence:[e:314..458] = [t:314..458]
;6)sentence:[e:460..816] = [t:460..816]
;7)sentence:[e:817..822] = [t:817..822]
;8)sentence:[e:823..889] = [t:823..889]
;9)sentence:[e:890..912] = [t:890..912]
;10)sentence:[e:913..1028] = [t:913..1028]
;11)sentence:[e:1029..1226] = [t:1029..1226]
;12)sentence:[e:1227..1385] = [t:1227..1385]
;13)sentence:[e:1386..1453] = [t:1386..1453]
;14)sentence:[e:1454..1462] = [t:1454..1462]
;15)sentence:[e:1463..1553] = [t:1463..1553]
;16)sentence:[e:1554..1700] = [t:1554..1700]
;17)sentence:[e:1701..1739] = [t:1701..1739]
;18)sentence:[e:1740..1836] = [t:1740..1836]
;19)sentence:[e:1837..1945] = [t:1837..1945]
;20)sentence:[e:1947..2004] = [t:1947..2004]
;21)sentence:[e:2005..2095] = [t:2005..2095]
;22)sentence:[e:2097..2109] = [t:2097..2109]
;23)sentence:[e:2110..2188] = [t:2110..2188]
;24)sentence:[e:2189..2295] = [t:2189..2295]
;25)sentence:[e:2296..2374] = [t:2296..2374]
;26)sentence:[e:2375..2453] = [t:2375..2453]
;27)sentence:[e:2454..2502] = [t:2454..2502]
;28)sentence:[e:2503..2580] = [t:2503..2580]
;29)section:[e:2584..2629] = [t:2584..2629]

;section 0 Span:0..25
;Gut  2002 Aug;51(2):200-6
(SEC
  (FRAG (NNP:[0..3] Gut) (CD:[5..9] 2002) (CC:[10..17] Aug;51-LRB-)
        (CD:[17..18] 2) (-RRB-:[18..19] -RRB-) (CD:[19..23] :200) (::[23..24] -)
        (CD:[24..25] 6)))

;sentence 1 Span:30..95
;Molecular characteristics of serrated adenomas of the colorectum.
;[59..94]:malignancy:"serrated adenomas of the colorectum"
(SENT
  (NP-HLN
    (NP (JJ:[30..39] Molecular) (NNS:[40..55] characteristics))
    (PP (IN:[56..58] of)
      (NP
        (NP (VBN:[59..67] serrated) (NNS:[68..76] adenomas))
        (PP (IN:[77..79] of)
          (NP (DT:[80..83] the) (NN:[84..94] colorectum)))))
    (.:[94..95] .)))

;section 2 Span:99..173
;Sawyer EJ, Cerar A, Hanby AM, Gorman P, Arends M, Talbot IC, Tomlinson IP.
(SEC
  (FRAG (NNP:[99..105] Sawyer) (NNP:[106..108] EJ) (,:[108..109] ,)
        (NNP:[110..115] Cerar) (NNP:[116..117] A) (,:[117..118] ,)
        (NNP:[119..124] Hanby) (VBP:[125..127] AM) (JJ:[127..128] ,)
        (NNP:[129..135] Gorman) (NNP:[136..137] P) (,:[137..138] ,)
        (NNP:[139..145] Arends) (NNP:[146..148] M,) (NNP:[149..155] Talbot)
        (NNP:[156..158] IC) (,:[158..159] ,) (NNP:[160..169] Tomlinson)
        (NNP:[170..172] IP) (.:[172..173] .)))

;section 3 Span:177..298
;Molecular and Population Genetics Laboratory, Imperial Cancer Research Fund, 
;London WC2A 3PX, UK. e.sawyer@icrf.icnet.uk
(SEC
  (FRAG (NNP:[177..186] Molecular) (CC:[187..190] and)
        (NNP:[191..201] Population) (NNP:[202..210] Genetics)
        (NNP:[211..221] Laboratory) (,:[221..222] ,) (NNP:[223..231] Imperial)
        (NNP:[232..238] Cancer) (NNP:[239..247] Research) (NNP:[248..252] Fund)
        (,:[252..253] ,) (NNP:[255..261] London) (NNP:[262..266] WC2A)
        (NNP:[267..270] 3PX) (,:[270..271] ,) (NNP:[272..275] UK.)
        (NNP:[276..277] e) (NNP:[277..289] .sawyer@icrf) (NNP:[289..295] .icnet)
        (.:[295..298] .uk)))

;sentence 4 Span:302..313
;BACKGROUND:
(SENT
  (NP (NN:[302..312] BACKGROUND) (::[312..313] :)))

;sentence 5 Span:314..458
;Serrated adenomas (SAs) of the colorectum combine architectural  features of
;hyperplastic polyps and cytological features of classical adenomas.
;[314..355]:malignancy:"Serrated adenomas (SAs) of the colorectum"
;[391..410]:malignancy:"hyperplastic polyps"
;[439..457]:malignancy:"classical adenomas"
(SENT
  (S
    (NP-SBJ
      (NP
        (NP (VBN:[314..322] Serrated) (NNS:[323..331] adenomas))
        (NP (-LRB-:[332..333] -LRB-) (NNS:[333..336] SAs)
            (-RRB-:[336..337] -RRB-)))
      (PP (IN:[338..340] of)
        (NP (DT:[341..344] the) (NN:[345..355] colorectum))))
    (VP (VBP:[356..363] combine)
      (NP
        (NP
          (NP (JJ:[364..377] architectural) (NNS:[379..387] features))
          (PP (IN:[388..390] of)
            (NP (JJ:[391..403] hyperplastic) (NNS:[404..410] polyps))))
        (CC:[411..414] and)
        (NP
          (NP (JJ:[415..426] cytological) (NNS:[427..435] features))
          (PP (IN:[436..438] of)
            (NP (JJ:[439..448] classical) (NNS:[449..457] adenomas))))))
    (.:[457..458] .)))

;sentence 6 Span:460..816
;Molecular studies comparing SAs and classical adenomas suggest that each may
;be  a distinct entity; in particular, it has been proposed that
;microsatellite  instability (MSI) distinguishes SAs from classical adenomas
;and that SAs and the  colorectal cancers arising from them develop along a
;pathway driven by low level  microsatellite instability (MSI-L).
;[488..491]:malignancy:"SAs"
;[496..514]:malignancy:"classical adenomas"
;[649..652]:malignancy:"SAs"
;[658..676]:malignancy:"classical adenomas"
;[686..689]:malignancy:"SAs"
;[699..717]:malignancy:"colorectal cancers"
(SENT
  (S
    (S
      (NP-SBJ
        (NP (JJ:[460..469] Molecular) (NNS:[470..477] studies))
        (VP (VBG:[478..487] comparing)
          (NP
            (NP (NNS:[488..491] SAs))
            (CC:[492..495] and)
            (NP (JJ:[496..505] classical) (NNS:[506..514] adenomas)))))
      (VP (VBP:[515..522] suggest)
        (SBAR (IN:[523..527] that)
          (S
            (NP-SBJ (DT:[528..532] each))
            (VP (MD:[533..536] may)
              (VP (VB:[537..539] be)
                (NP-PRD (DT:[541..542] a) (JJ:[543..551] distinct)
                        (NN:[552..558] entity))))))))
    (::[558..559] ;)
    (S
      (PP (IN:[560..562] in)
        (NP (JJ:[563..573] particular)))
      (,:[573..574] ,)
      (NP-SBJ-2
        (NP (PRP:[575..577] it))
        (SBAR-1 (-NONE-:[577..577] *EXP*)))
      (VP (VBZ:[578..581] has)
        (VP (VBN:[582..586] been)
          (VP (VBN:[587..595] proposed)
            (NP-2 (-NONE-:[595..595] *))
            (SBAR-1
              (SBAR (IN:[596..600] that)
                (S
                  (NP-SBJ
                    (NP (NN:[601..615] microsatellite)
                        (NN:[617..628] instability))
                    (NP (-LRB-:[629..630] -LRB-) (NN:[630..633] MSI)
                        (-RRB-:[633..634] -RRB-)))
                  (VP (VBZ:[635..648] distinguishes)
                    (NP (NNS:[649..652] SAs))
                    (PP-CLR (IN:[653..657] from)
                      (NP (JJ:[658..667] classical) (NNS:[668..676] adenomas))))))
              (CC:[677..680] and)
              (SBAR (IN:[681..685] that)
                (S
                  (NP-SBJ
                    (NP (NNS:[686..689] SAs))
                    (CC:[690..693] and)
                    (NP
                      (NP (DT:[694..697] the)
                         (JJ:[699..709] colorectal) (NNS:[710..717] cancers))
                      (VP (VBG:[718..725] arising)
                        (PP (IN:[726..730] from)
                          (NP (PRP:[731..735] them))))))
                  (VP (VBP:[736..743] develop)
                    (PP (IN:[744..749] along)
                      (NP
                        (NP (DT:[750..751] a) (NN:[752..759] pathway))
                        (VP (VBN:[760..766] driven)
                          (NP (-NONE-:[766..766] *))
                          (PP (IN:[767..769] by)
                            (NP
                              (NP (JJ:[770..773] low) (NN:[774..779] level)
                                  (NN:[781..795] microsatellite)
                                  (NN:[796..807] instability))
                              (NP (-LRB-:[808..809] -LRB-) (NN:[809..814] MSI-L)
                                  (-RRB-:[814..815] -RRB-)))))))))))))))
    (.:[815..816] .)))

;sentence 7 Span:817..822
;AIMS:
(SENT
  (NP (NNS:[817..821] AIMS) (::[821..822] :)))

;sentence 8 Span:823..889
;To define the molecular  characteristics of SAs of the colorectum.
;[867..888]:malignancy:"SAs of the colorectum"
(SENT
  (S
    (NP-SBJ (-NONE-:[823..823] *))
    (VP (TO:[823..825] To)
      (VP (VB:[826..832] define)
        (NP
          (NP (DT:[833..836] the) (JJ:[837..846] molecular)
              (NNS:[848..863] characteristics))
          (PP (IN:[864..866] of)
            (NP
              (NP (NNS:[867..870] SAs))
              (PP (IN:[871..873] of)
                (NP (DT:[874..877] the) (NN:[878..888] colorectum))))))))
    (.:[888..889] .)))

;sentence 9 Span:890..912
;MATERIALS AND METHODS:
(SENT
  (NP (NNS:[890..899] MATERIALS) (CC:[900..903] AND) (NNS:[904..911] METHODS)
      (::[911..912] :)))

;sentence 10 Span:913..1028
;We analysed 39  SAs from 27 patients, including eight SAs from patients with
;familial  adenomatous polyposis (FAP).
;[929..932]:malignancy:"SAs"
;[967..970]:malignancy:"SAs"
;[990..1021]:malignancy:"familial  adenomatous polyposis"
;[1023..1026]:malignancy:"FAP"
(SENT
  (S
    (NP-SBJ (PRP:[913..915] We))
    (VP (VBD:[916..924] analysed)
      (NP
        (NP (CD:[925..927] 39) (NNS:[929..932] SAs))
        (PP (IN:[933..937] from)
          (NP (CD:[938..940] 27) (NNS:[941..949] patients)))
        (,:[949..950] ,)
        (PP (VBG:[951..960] including)
          (NP
            (NP (CD:[961..966] eight) (NNS:[967..970] SAs))
            (PP (IN:[971..975] from)
              (NP
                (NP (NNS:[976..984] patients))
                (PP (IN:[985..989] with)
                  (NP
                    (NP (JJ:[990..998] familial) (JJ:[1000..1011] adenomatous)
                        (NN:[1012..1021] polyposis))
                    (NP (-LRB-:[1022..1023] -LRB-) (NN:[1023..1026] FAP)
                        (-RRB-:[1026..1027] -RRB-))))))))))
    (.:[1027..1028] .)))

;sentence 11 Span:1029..1226
;We screened these polyps for selected molecular  changes, including loss of
;heterozygosity (LOH) close to APC (5q21) and CRAC1  (15q13-q22), MSI, and
;mutations of K-ras, APC, p53, and beta-catenin.
;[1047..1053]:malignancy:"polyps"
;[1097..1119]:variation-type:"loss of heterozygosity"
;[1121..1124]:variation-type:"LOH"
;[1135..1138]:gene-rna:"APC"
;[1140..1144]:variation-location:"5q21"
;[1150..1155]:gene-rna:"CRAC1"
;[1158..1167]:variation-location:"15q13-q22"
;[1192..1197]:gene-rna:"K-ras"
;[1199..1202]:gene-rna:"APC"
;[1204..1207]:gene-rna:"p53"
;[1213..1225]:gene-rna:"beta-catenin"
(SENT
  (S
    (NP-SBJ (PRP:[1029..1031] We))
    (VP (VBD:[1032..1040] screened)
      (NP (DT:[1041..1046] these) (NNS:[1047..1053] polyps))
      (PP-PRP (IN:[1054..1057] for)
        (NP
          (NP (VBN:[1058..1066] selected) (JJ:[1067..1076] molecular)
              (NNS:[1078..1085] changes))
          (,:[1085..1086] ,)
          (PP (VBG:[1087..1096] including)
            (NP
              (NP
                (NP
                  (NP
                    (NP (NN:[1097..1101] loss))
                    (PP (IN:[1102..1104] of)
                      (NP (NN:[1105..1119] heterozygosity))))
                  (NP (-LRB-:[1120..1121] -LRB-) (NN:[1121..1124] LOH)
                      (-RRB-:[1124..1125] -RRB-)))
                (ADJP (JJ:[1126..1131] close)
                  (PP (TO:[1132..1134] to)
                    (NP
                      (NP (NN:[1135..1138] APC)
                        (PRN (-LRB-:[1139..1140] -LRB-)
                          (NP (NN:[1140..1144] 5q21))
                          (-RRB-:[1144..1145] -RRB-)))
                      (CC:[1146..1149] and)
                      (NP (NN:[1150..1155] CRAC1)
                        (PRN (-LRB-:[1157..1158] -LRB-)
                          (NP (NN:[1158..1163] 15q13) (HYPH:[1163..1164] -)
                              (NN:[1164..1167] q22))
                          (-RRB-:[1167..1168] -RRB-)))))))
              (,:[1168..1169] ,)
              (NP (NN:[1170..1173] MSI))
              (,:[1173..1174] ,) (CC:[1175..1178] and)
              (NP
                (NP (NNS:[1179..1188] mutations))
                (PP (IN:[1189..1191] of)
                  (NP (NN:[1192..1197] K-ras) (,:[1197..1198] ,)
                      (NN:[1199..1202] APC) (,:[1202..1203] ,)
                      (NN:[1204..1207] p53) (,:[1207..1208] ,)
                      (CC:[1209..1212] and) (NN:[1213..1225] beta-catenin)))))))))
    (.:[1225..1226] .)))

;sentence 12 Span:1227..1385
;Expression  patterns of beta-catenin, p53, MLH1, MSH2, E-cadherin, and
;O(6)-methylguanine  DNA methyltransferase (MGMT) were assessed by
;immunohistochemistry.
;[1251..1263]:gene-protein:"beta-catenin"
;[1265..1268]:gene-protein:"p53"
;[1270..1274]:gene-protein:"MLH1"
;[1276..1280]:gene-protein:"MSH2"
;[1282..1292]:gene-protein:"E-cadherin"
;[1298..1339]:gene-protein:"O(6)-methylguanine  DNA methyltransferase"
;[1341..1345]:gene-protein:"MGMT"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[1227..1237] Expression) (NNS:[1239..1247] patterns))
      (PP (IN:[1248..1250] of)
        (NP
          (NP (NN:[1251..1263] beta-catenin))
          (,:[1263..1264] ,)
          (NP (NN:[1265..1268] p53))
          (,:[1268..1269] ,)
          (NP (NN:[1270..1274] MLH1))
          (,:[1274..1275] ,)
          (NP (NN:[1276..1280] MSH2))
          (,:[1280..1281] ,)
          (NP (NN:[1282..1292] E-cadherin))
          (,:[1292..1293] ,) (CC:[1294..1297] and)
          (NP
            (NP (NN:[1298..1316] O-LRB-6-RRB--methylguanine)
                (NN:[1318..1321] DNA) (NN:[1322..1339] methyltransferase))
            (NP (-LRB-:[1340..1341] -LRB-) (NN:[1341..1345] MGMT)
                (-RRB-:[1345..1346] -RRB-))))))
    (VP (VBD:[1347..1351] were)
      (VP (VBN:[1352..1360] assessed)
        (NP-1 (-NONE-:[1360..1360] *))
        (PP-MNR (IN:[1361..1363] by)
          (NP (NN:[1364..1384] immunohistochemistry)))))
    (.:[1384..1385] .)))

;sentence 13 Span:1386..1453
;Comparative  genomic hybridisation was performed on several polyps.
;[1446..1452]:malignancy:"polyps"
(SENT
  (S
    (NP-SBJ-1 (JJ:[1386..1397] Comparative) (JJ:[1399..1406] genomic)
              (NN:[1407..1420] hybridisation))
    (VP (VBD:[1421..1424] was)
      (VP (VBN:[1425..1434] performed)
        (NP-1 (-NONE-:[1434..1434] *))
        (PP (IN:[1435..1437] on)
          (NP (JJ:[1438..1445] several) (NNS:[1446..1452] polyps)))))
    (.:[1452..1453] .)))

;sentence 14 Span:1454..1462
;RESULTS:
(SENT
  (NP (NNS:[1454..1461] RESULTS) (::[1461..1462] :)))

;sentence 15 Span:1463..1553
;MSI was rare  (<5% cases) and there was no loss of expression of mismatch
;repair proteins.
;[1528..1552]:gene-protein:"mismatch repair proteins"
(SENT
  (S
    (S
      (NP-SBJ (NN:[1463..1466] MSI))
      (VP (VBD:[1467..1470] was)
        (ADJP-PRD (JJ:[1471..1475] rare)
          (PRN (-LRB-:[1477..1478] -LRB-)
            (NP
              (NML
                (QP (SYM:[1478..1479] <) (CD:[1479..1480] 5))
                (NN:[1480..1481] %))
              (NNS:[1482..1487] cases))
            (-RRB-:[1487..1488] -RRB-)))))
    (CC:[1489..1492] and)
    (S
      (NP-SBJ (EX:[1493..1498] there))
      (VP (VBD:[1499..1502] was)
        (NP-PRD
          (NP (DT:[1503..1505] no) (NN:[1506..1510] loss))
          (PP (IN:[1511..1513] of)
            (NP
              (NP (NN:[1514..1524] expression))
              (PP (IN:[1525..1527] of)
                (NP
                  (NML (NN:[1528..1536] mismatch) (NN:[1537..1543] repair))
                  (NNS:[1544..1552] proteins))))))))
    (.:[1552..1553] .)))

;sentence 16 Span:1554..1700
;Wnt  pathway abnormalities (APC mutation/LOH, beta-catenin mutation/nuclear 
;expression) occurred in 11 SAs, including 6/31 (19%) non-FAP tumours.
;[1554..1557]:gene-protein:"Wnt"
;[1582..1585]:gene-rna:"APC"
;[1586..1594]:variation-event:"mutation"
;[1595..1598]:variation-type:"LOH"
;[1600..1612]:gene-generic:"beta-catenin"
;[1658..1661]:malignancy:"SAs"
;[1684..1699]:malignancy:"non-FAP tumours"
(SENT
  (S
    (NP-SBJ
      (NML (NN:[1554..1557] Wnt) (NN:[1559..1566] pathway))
      (NNS:[1567..1580] abnormalities)
      (PRN (-LRB-:[1581..1582] -LRB-)
        (NP
          (NP
            (NP (NN:[1582..1585] APC) (NN:[1586..1594] mutation))
            (SYM:[1594..1595] /)
            (NP (NN:[1595..1598] LOH)))
          (,:[1598..1599] ,)
          (NP
            (NP (NN:[1600..1612] beta-catenin) (NN:[1613..1621] mutation))
            (SYM:[1621..1622] /)
            (NP (JJ:[1622..1629] nuclear) (NN:[1631..1641] expression))))
        (-RRB-:[1641..1642] -RRB-)))
    (VP (VBD:[1643..1651] occurred)
      (PP-LOC (IN:[1652..1654] in)
        (NP
          (NP (CD:[1655..1657] 11) (NNS:[1658..1661] SAs))
          (,:[1661..1662] ,)
          (PP (VBG:[1663..1672] including)
            (NP
              (NP (CD:[1673..1674] 6))
              (PP (SYM:[1674..1675] /)
                (NP (CD:[1675..1677] 31)
                  (PRN (-LRB-:[1678..1679] -LRB-)
                    (NP (CD:[1679..1681] 19) (NN:[1681..1682] %))
                    (-RRB-:[1682..1683] -RRB-))
                  
                  (NML (AFX:[1684..1687] non) (HYPH:[1687..1688] -)
                       (NN:[1688..1691] FAP))
                  (NNS:[1692..1699] tumours))))))))
    (.:[1699..1700] .)))

;sentence 17 Span:1701..1739
;CRAC1 LOH  occurred in 23% of tumours.
;[1701..1706]:gene-rna:"CRAC1"
;[1707..1710]:variation-type:"LOH"
;[1731..1738]:malignancy:"tumours"
(SENT
  (S
    (NP-SBJ (NN:[1701..1706] CRAC1) (NN:[1707..1710] LOH))
    (VP (VBD:[1712..1720] occurred)
      (PP-LOC (IN:[1721..1723] in)
        (NP
          (NP (CD:[1724..1726] 23) (NN:[1726..1727] %))
          (PP (IN:[1728..1730] of)
            (NP (NNS:[1731..1738] tumours))))))
    (.:[1738..1739] .)))

;sentence 18 Span:1740..1836
;K-ras mutations and p53 mutations/overexpression  were found in 15% and 8% of
;SAs, respectively.
;[1740..1745]:gene-rna:"K-ras"
;[1760..1763]:gene-generic:"p53"
;[1818..1821]:malignancy:"SAs"
(SENT
  (S
    (NP-SBJ-2
      (NP (NN:[1740..1745] K-ras) (NNS:[1746..1755] mutations))
      (CC:[1756..1759] and)
      (NP
        (NP
          (NML-1 (NN:[1760..1763] p53))
          (NNS:[1764..1773] mutations))
        (SYM:[1773..1774] /)
        (NP
          (NML-1 (-NONE-:[1774..1774] *P*))
          (NN:[1774..1788] overexpression))))
    (VP (VBD:[1790..1794] were)
      (VP (VBN:[1795..1800] found)
        (NP-2 (-NONE-:[1800..1800] *))
        (PP (IN:[1801..1803] in)
          (NP
            (NP
              (NP (CD:[1804..1806] 15) (NN:[1806..1807] %))
              (CC:[1808..1811] and)
              (NP (CD:[1812..1813] 8) (NN:[1813..1814] %)))
            (PP (IN:[1815..1817] of)
              (NP (NNS:[1818..1821] SAs)))))
        (,:[1821..1822] ,)
        (ADVP (RB:[1823..1835] respectively))))
    (.:[1835..1836] .)))

;sentence 19 Span:1837..1945
;Loss of MGMT expression occurred  in 18% of polyps and showed a borderline
;association with K-ras mutations.
;[1845..1849]:gene-protein:"MGMT"
;[1881..1887]:malignancy:"polyps"
;[1929..1934]:gene-rna:"K-ras"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1837..1841] Loss))
      (PP (IN:[1842..1844] of)
        (NP (NN:[1845..1849] MGMT) (NN:[1850..1860] expression))))
    (VP
      (VP (VBD:[1861..1869] occurred)
        (PP-LOC (IN:[1871..1873] in)
          (NP
            (NP (CD:[1874..1876] 18) (NN:[1876..1877] %))
            (PP (IN:[1878..1880] of)
              (NP (NNS:[1881..1887] polyps))))))
      (CC:[1888..1891] and)
      (VP (VBD:[1892..1898] showed)
        (NP
          (NP (DT:[1899..1900] a) (JJ:[1901..1911] borderline)
              (NN:[1912..1923] association))
          (PP (IN:[1924..1928] with)
            (NP (NN:[1929..1934] K-ras) (NNS:[1935..1944] mutations))))))
    (.:[1944..1945] .)))

;sentence 20 Span:1947..2004
;Aberrant E-cadherin expression was found in seven polyps.
;[1956..1966]:gene-protein:"E-cadherin"
;[1997..2003]:malignancy:"polyps"
(SENT
  (S
    (NP-SBJ-1 (JJ:[1947..1955] Aberrant) (NN:[1956..1966] E-cadherin)
              (NN:[1967..1977] expression))
    (VP (VBD:[1978..1981] was)
      (VP (VBN:[1982..1987] found)
        (NP-1 (-NONE-:[1987..1987] *))
        (PP-LOC (IN:[1988..1990] in)
          (NP (CD:[1991..1996] seven) (NNS:[1997..2003] polyps)))))
    (.:[2003..2004] .)))

;sentence 21 Span:2005..2095
;Comparative genomic  hybridisation detected no gains or deletions of
;chromosomal material.
(SENT
  (S
    (NP-SBJ (JJ:[2005..2016] Comparative) (JJ:[2017..2024] genomic)
            (NN:[2026..2039] hybridisation))
    (VP (VBD:[2040..2048] detected)
      (NP
        (NP
          (NP (DT:[2049..2051] no) (NNS:[2052..2057] gains))
          (CC:[2058..2060] or)
          (NP (NNS:[2061..2070] deletions)))
        (PP (IN:[2071..2073] of)
          (NP (JJ:[2074..2085] chromosomal) (NN:[2086..2094] material)))))
    (.:[2094..2095] .)))

;sentence 22 Span:2097..2109
;CONCLUSIONS:
(SENT
  (NP (NNS:[2097..2108] CONCLUSIONS) (::[2108..2109] :)))

;sentence 23 Span:2110..2188
;The serrated pathway of colorectal tumorigenesis appears to be 
;heterogeneous.
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[2110..2113] The) (VBN:[2114..2122] serrated)
          (NN:[2123..2130] pathway))
      (PP (IN:[2131..2133] of)
        (NP (JJ:[2134..2144] colorectal) (NN:[2145..2158] tumorigenesis))))
    (VP (VBZ:[2159..2166] appears)
      (S
        (NP-SBJ-1 (-NONE-:[2166..2166] *))
        (VP (TO:[2167..2169] to)
          (VP (VB:[2170..2172] be)
            (ADJP-PRD (JJ:[2174..2187] heterogeneous))))))
    (.:[2187..2188] .)))

;sentence 24 Span:2189..2295
;In common with classical adenomas, some SAs develop along  pathways involving
;changes in APC/beta-catenin.
;[2204..2222]:malignancy:"classical adenomas"
;[2229..2232]:malignancy:"SAs"
;[2278..2281]:gene-rna:"APC"
;[2282..2294]:gene-rna:"beta-catenin"
(SENT
  (S
    (PP (IN:[2189..2191] In)
      (NP
        (NP (NN:[2192..2198] common))
        (PP (IN:[2199..2203] with)
          (NP (JJ:[2204..2213] classical) (NNS:[2214..2222] adenomas)))))
    (,:[2222..2223] ,)
    (NP-SBJ (DT:[2224..2228] some) (NNS:[2229..2232] SAs))
    (VP (VBP:[2233..2240] develop)
      (PP (IN:[2241..2246] along)
        (NP
          (NP (NNS:[2248..2256] pathways))
          (VP (VBG:[2257..2266] involving)
            (NP
              (NP (NNS:[2267..2274] changes))
              (PP (IN:[2275..2277] in)
                (NP (NN:[2278..2281] APC) (SYM:[2281..2282] /)
                    (NN:[2282..2294] beta-catenin))))))))
    (.:[2294..2295] .)))

;sentence 25 Span:2296..2374
;SAs rarely show MSI or any  evidence of chromosomal-scale genetic
;instability.
;[2296..2299]:malignancy:"SAs"
(SENT
  (S
    (NP-SBJ (NNS:[2296..2299] SAs))
    (ADVP (RB:[2300..2306] rarely))
    (VP (VBP:[2307..2311] show)
      (NP
        (NP (NN:[2312..2315] MSI))
        (CC:[2316..2318] or)
        (NP
          (NP (DT:[2319..2322] any) (NN:[2324..2332] evidence))
          (PP (IN:[2333..2335] of)
            (NP
              (NML (JJ:[2336..2347] chromosomal) (HYPH:[2347..2348] -)
                   (NN:[2348..2353] scale))
              (JJ:[2354..2361] genetic) (NN:[2362..2373] instability))))))
    (.:[2373..2374] .)))

;sentence 26 Span:2375..2453
;K-ras mutations may however  be less common in SAs than in classical
;adenomas.
;[2375..2380]:gene-rna:"K-ras"
;[2422..2425]:malignancy:"SAs"
;[2434..2452]:malignancy:"classical adenomas"
(SENT
  (S
    (NP-SBJ (NN:[2375..2380] K-ras) (NNS:[2381..2390] mutations))
    (VP (MD:[2391..2394] may)
      (ADVP (RB:[2395..2402] however))
      (VP (VB:[2404..2406] be)
        (ADJP-PRD
          (ADJP (RBR:[2407..2411] less) (JJ:[2412..2418] common))
          (PP-1 (-NONE-:[2418..2418] *ICH*)))
        (PP-LOC (IN:[2419..2421] in)
          (NP (NNS:[2422..2425] SAs)))
        (PP-1 (IN:[2426..2430] than)
          (PP-LOC (IN:[2431..2433] in)
            (NP (JJ:[2434..2443] classical) (NNS:[2444..2452] adenomas))))))
    (.:[2452..2453] .)))

;sentence 27 Span:2454..2502
;Some SAs may harbour changes  in the CRAC1 gene.
;[2459..2462]:malignancy:"SAs"
;[2491..2496]:gene-rna:"CRAC1"
(SENT
  (S
    (NP-SBJ (DT:[2454..2458] Some) (NNS:[2459..2462] SAs))
    (VP (MD:[2463..2466] may)
      (VP (VB:[2467..2474] harbour)
        (NP
          (NP (NNS:[2475..2482] changes))
          (PP-LOC (IN:[2484..2486] in)
            (NP (DT:[2487..2490] the) (NN:[2491..2496] CRAC1)
                (NN:[2497..2501] gene))))))
    (.:[2501..2502] .)))

;sentence 28 Span:2503..2580
;Changes in known genes do not account for the growth of the  majority of
;SAs.
;[2576..2579]:malignancy:"SAs"
(SENT
  (S
    (NP-SBJ
      (NP (NNS:[2503..2510] Changes))
      (PP-LOC (IN:[2511..2513] in)
        (NP (VBN:[2514..2519] known) (NNS:[2520..2525] genes))))
    (VP (VBP:[2526..2528] do) (RB:[2529..2532] not)
      (VP (VB:[2533..2540] account)
        (PP-CLR (IN:[2541..2544] for)
          (NP
            (NP (DT:[2545..2548] the) (NN:[2549..2555] growth))
            (PP (IN:[2556..2558] of)
              (NP
                (NP (DT:[2559..2562] the) (NN:[2564..2572] majority))
                (PP (IN:[2573..2575] of)
                  (NP (NNS:[2576..2579] SAs)))))))))
    (.:[2579..2580] .)))

;section 29 Span:2584..2629
;PMID: 12117880 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2584..2588] PMID) (::[2588..2589] :) (CD:[2590..2598] 12117880)
        (NN:[2599..2600] -LSB-) (NNP:[2600..2606] PubMed) (::[2607..2608] -)
        (NN:[2609..2616] indexed) (IN:[2617..2620] for)
        (NNP:[2621..2629] MEDLINE-RSB-)))
